MedWatch

Novo Nordisk after massive deal: We are still looking for acquisitions and license agreements

Novo Nordisk has purchased the rights for a drug against two rare blood disorders in a potential million dollar deal, but according to Executive Vice President and Chief Science Officer, Mads Krogsgaard Thomsen, Novo is still searching the market for external possibilities.

Photo: /ritzau scanpix/Claus Bech

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Nyt milliontab i Labflex

For andet år i træk viser regnskabet for laboratoriefirmaet Labflex et stort underskud. Ledelsen forventer for 2018 endnu et år med tab.

David Solomon lander nyt topjob

Mindre end tre måneder efter at være trådt tilbage som adm. direktør i amerikansk biotekselskab efter kontrovers om brug af et kreditkort er den tidligere Zealand Pharma-topchef David Solomon atter tilbage i direktørstolen. Denne gang i et britisk biotekselskab.

Related articles